Reviewed,
UniProtKB/Swiss-Prot P10912 (GHR_HUMAN)
Last modified
November 25, 2008.
Version 113.
History...
Clusters with 100%,
90%,
50% identity |
Documents (7) |
Third-party data |
Customize display | text xml rdf/xml gff fasta |
Names and origin
| Protein names | Recommended name: Growth hormone receptor Short name=GH receptor Alternative name(s): Somatotropin receptor Cleaved into the following chain: 1- Recommended name: Growth hormone-binding protein Short name=GH-binding protein Short name=GHBP Alternative name(s): Serum-binding protein | ||
| Gene names |
| ||
| Organism | Homo sapiens (Human) | ||
| Taxonomic identifier | 9606 [NCBI] | ||
| Taxonomic lineage | Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo |
Protein attributes
| Sequence length | 638 AA. |
| Sequence status | Complete. |
| Sequence processing | The displayed sequence is further processed into a mature form. |
| Protein existence | Evidence at protein level. |
General annotation (Comments)
| Function | Receptor for pituitary gland growth hormone involved in regulating postnatal body growth. On ligand binding, couples to the JAK2/STAT5 pathway By similarity. The soluble form (GHBP) acts as a reservoir of growth hormone in plasma and may be a modulator/inhibitor of GH signaling. Isoform 2 up-regulates the production of GHBP and acts as a negative inhibitor of GH signaling. |
| Subunit structure | On growth hormone (GH) binding, forms homodimers and binds JAK2 via a box 1-containing domain By similarity. Binding to SOCS3 inhibits JAK2 activation, binding to CIS and SOCS2 inhibits STAT5 activation By similarity. Interacts with ADAM17 By similarity. |
| Subcellular location | Cell membrane; Single-pass type I membrane protein. Note= On growth hormone binding, GHR is ubiquitinated, internalized, down-regulated and transported into a degradative or non-degradative pathway By similarity. Isoform 2: Cell membrane; Single-pass type I membrane protein. Note= Remains fixed to the cell membrane and is not internalized. Growth hormone-binding protein: Secreted. |
| Tissue specificity | Expressed in various tissues with high expression in liver and skeletal muscle. Isoform 4 is predominantly expressed in kidney, bladder, adrenal gland and brain stem. In the placenta, isoform 1 predominantly expressed in chorion and decidua, isoform 4 highly expressed in villi. Isoform 2 is expressed in lung, stomach and muscle. Low levels in liver. |
| Domain | The WSXWS motif appears to be necessary for proper protein folding and thereby efficient intracellular transport and cell-surface receptor binding. The box 1 motif is required for JAK interaction and/or activation. The extracellular domain is the ligand-binding domain representing the growth hormone-binding protein (GHBP). The ubiquitination-dependent endocytosis motif (UbE) is required for recruitment of the ubiquitin conjugation system on to the receptor and for its internalization. |
| Post-translational modification | The soluble form (GHBP) is produced by phorbol ester-promoted proteolytic cleavage at the cell surface (shedding) by ADAM17/TACE. Shedding is inhibited by growth hormone (GH) binding to the receptor probably due to a conformational change in GHR rendering the receptor inaccessible to ADAM17 By similarity. On GH binding, phosphorylated on tyrosine residues in the cytoplasmic domain by JAK2 By similarity. On ligand binding, ubiquitinated on lysine residues in the cytoplasmic domain. This ubiquitination is not sufficient for GHR internalization By similarity. |
| Polymorphism | Genetic variation in GHR may act as phenotype modifier in familial hypercholesterolemia [MIM:143890] patients carrying a mutation in the LDLR gene. |
| Involvement in disease | Defects in GHR are a cause of Laron dwarfism [MIM:262500]; also known as pituitary dwarfism II; Laron-type pituitary dwarfism I (LTD1) or Laron syndrome (LS). It is the most severe form of growth hormone insensitivity (GHI) characterized by growth impairment, dysmorphic facial features and truncal obesity. Levels of GHBP are low or undetectable in patients with Laron syndrome. Defects in GHR may be a cause of short stature [MIM:604271]. Short stature is defined by a subnormal rate of growth. |
| Sequence similarities | Belongs to the type I cytokine receptor family. Type 1 subfamily. Contains 1 fibronectin type-III domain. |
Ontologies
Keywords | |
|---|---|
| Biological process | Endocytosis |
| Cellular component | Cell membrane Membrane Secreted |
| Coding sequence diversity | Alternative splicing Polymorphism |
| Disease | Disease mutation Dwarfism |
| Domain | Signal Transmembrane |
| Molecular function | Receptor |
| PTM | Glycoprotein Phosphoprotein Ubl conjugation |
| Technical term | 3D-structure Direct protein sequencing |
Gene Ontology (GO) | |
| Biological process | endocytosis Inferred from electronic annotation. Source: UniProtKB-KW growthTraceable author statement. Source: ProtInc skeletal system developmentTraceable author statement. Source: ProtInc |
| Cellular component | extracellular region Inferred from electronic annotation. Source: UniProtKB-KW integral to plasma membrane Ref.1Traceable author statement. Source: ProtInc |
| Molecular function | growth hormone receptor activity Traceable author statement. Source: ProtInc protein binding Ref.13Inferred from physical interaction. Source: IntAct |
| Complete GO annotation... | |
Binary interactions
With | Entry | #Exp. | IntAct | Notes |
|---|---|---|---|---|
| CRK | P46108 | 1 | EBI-286316,EBI-886 | |
| DUSP7 | Q16829 | 1 | EBI-286316,EBI-1265847 | |
| GH1 | P01241 | 2 | EBI-286316,EBI-1026046 | |
| GRB2 | P62993 | 1 | EBI-286316,EBI-401755 | |
| NCK1 | P16333 | 1 | EBI-286316,EBI-389883 | |
| Ncoa6 | Q9JLI4 | 1 | EBI-286316,EBI-286271 | From a different organism. |
| PIK3R1 | P27986 | 1 | EBI-286316,EBI-79464 | |
| PLCG1 | P19174 | 1 | EBI-286316,EBI-79387 | |
| PTPN1 | P18031 | 2 | EBI-286316,EBI-968788 | |
| PTPN2 | P17706 | 2 | EBI-286316,EBI-984930 | |
| PTPN3 | P26045 | 2 | EBI-286316,EBI-1047946 | |
| PTPN9 | P43378 | 1 | EBI-286316,EBI-742898 | |
| PTPRB | P23467 | 1 | EBI-286316,EBI-1265766 | |
| PTPRH | Q9HD43 | 2 | EBI-286316,EBI-1267176 |
Alternative products
| This entry describes 4 isoforms produced by alternative splicing. [Align] [Select] | ||||||
| Isoform 1 (identifier: P10912-1) Also known as: GHRfl; This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry. | ||||||
| Isoform 2 (identifier: P10912-2) Also known as: GHRtr; GHR1-279; The sequence of this isoform differs from the canonical sequence as follows: 292-297: RIKMLI → SSSSKD 298-638: Missing. | ||||||
| Notes: Remains fixed to the cell membrane and is not internalized. | ||||||
| Isoform 3 (identifier: P10912-3) Also known as: GHR1-277; The sequence of this isoform differs from the canonical sequence as follows: 292-294: RIK → KEN 295-638: Missing. | ||||||
| Isoform 4 (identifier: P10912-4) Also known as: GHRd3; The sequence of this isoform differs from the canonical sequence as follows: 24-24: A → D 25-46: Missing. | ||||||
| Notes: Arises by species-specific retrovirus-mediated alternative splice mimicry. |
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | Feature identifier | |||||||||||||||||||||||||||||||||
Molecule processing | ||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal peptide | 1 – 18 | 18 | Potential | |||||||||||||||||||||||||||||||||||
| Chain | 19 – 638 | 620 | Growth hormone receptor | PRO_0000010957 | ||||||||||||||||||||||||||||||||||
| Chain | 19 – ? | Growth hormone-binding protein | PRO_0000010958 | |||||||||||||||||||||||||||||||||||
Regions | ||||||||||||||||||||||||||||||||||||||
| Topological domain | 19 – 264 | 246 | Extracellular Potential | |||||||||||||||||||||||||||||||||||
| Transmembrane | 265 – 288 | 24 | Potential | |||||||||||||||||||||||||||||||||||
| Topological domain | 289 – 638 | 350 | Cytoplasmic Potential | |||||||||||||||||||||||||||||||||||
| Domain | 149 – 251 | 103 | Fibronectin type-III | |||||||||||||||||||||||||||||||||||
| Region | 260 – 262 | 3 | Required for ADAM17-mediated proteolysis By similarity | |||||||||||||||||||||||||||||||||||
| Motif | 240 – 244 | 5 | WSXWS motif | |||||||||||||||||||||||||||||||||||
| Motif | 297 – 305 | 9 | Box 1 motif | |||||||||||||||||||||||||||||||||||
| Motif | 340 – 349 | 10 | UbE motif | |||||||||||||||||||||||||||||||||||
Sites | ||||||||||||||||||||||||||||||||||||||
| Site | 345 | 1 | Required for endocytosis and down-regulation By similarity | |||||||||||||||||||||||||||||||||||
Amino acid modifications | ||||||||||||||||||||||||||||||||||||||
| Glycosylation | 46 | 1 | N-linked (GlcNAc...) Potential | |||||||||||||||||||||||||||||||||||
| Glycosylation | 115 | 1 | N-linked (GlcNAc...) Potential | |||||||||||||||||||||||||||||||||||
| Glycosylation | 156 | 1 | N-linked (GlcNAc...) Potential | |||||||||||||||||||||||||||||||||||
| Glycosylation | 161 | 1 | N-linked (GlcNAc...) Potential | |||||||||||||||||||||||||||||||||||
| Glycosylation | 200 | 1 | N-linked (GlcNAc...) Potential | |||||||||||||||||||||||||||||||||||
| Disulfide bond | 56 ↔ 66 | |||||||||||||||||||||||||||||||||||||
| Disulfide bond | 101 ↔ 112 | |||||||||||||||||||||||||||||||||||||
| Disulfide bond | 126 ↔ 140 | |||||||||||||||||||||||||||||||||||||
Natural variations | ||||||||||||||||||||||||||||||||||||||
| Alternative sequence | 24 | 1 | A → D in isoform 4. | VSP_010225 | ||||||||||||||||||||||||||||||||||
| Alternative sequence | 25 – 46 | 22 | Missing in isoform 4. | VSP_010226 | ||||||||||||||||||||||||||||||||||
| Alternative sequence | 292 – 297 | 6 | RIKMLI → SSSSKD in isoform 2. | VSP_010227 | ||||||||||||||||||||||||||||||||||
| Alternative sequence | 292 – 294 | 3 | RIK → KEN in isoform 3. | VSP_010229 | ||||||||||||||||||||||||||||||||||
| Alternative sequence | 295 – 638 | 344 | Missing in isoform 3. | VSP_010230 | ||||||||||||||||||||||||||||||||||
| Alternative sequence | 298 – 638 | 341 | Missing in isoform 2. | VSP_010228 | ||||||||||||||||||||||||||||||||||
| Natural variant | 56 | 1 | C → S in Laron dwarfism. | VAR_018426 | ||||||||||||||||||||||||||||||||||
| Natural variant | 58 | 1 | S → L in Laron dwarfism. | VAR_018427 | ||||||||||||||||||||||||||||||||||
| Natural variant | 62 | 1 | E → K in short stature; idiopathic autosomal. | VAR_002708 | ||||||||||||||||||||||||||||||||||
| Natural variant | 68 | 1 | W → R in Laron dwarfism. | VAR_018428 | ||||||||||||||||||||||||||||||||||
| Natural variant | 89 | 1 | R → K in Laron dwarfism. | VAR_002709 | ||||||||||||||||||||||||||||||||||
| Natural variant | 114 | 1 | F → S in Laron dwarfism; loss of ability to bind ligand. | VAR_002710 | ||||||||||||||||||||||||||||||||||
| Natural variant | 143 | 1 | V → A in Laron dwarfism. | VAR_002711 | ||||||||||||||||||||||||||||||||||
| Natural variant | 149 | 1 | P → Q in Laron dwarfism; disrupts GH binding. | VAR_018429 | ||||||||||||||||||||||||||||||||||
| Natural variant | 162 | 1 | V → D in Laron dwarfism. | VAR_002712 | ||||||||||||||||||||||||||||||||||
| Natural variant | 162 | 1 | V → F: dbSNP rs6413484. | VAR_020002 | ||||||||||||||||||||||||||||||||||
| Natural variant | 162 | 1 | V → I in short stature; idiopathic autosomal. | VAR_018430 | ||||||||||||||||||||||||||||||||||
| Natural variant | 170 | 1 | D → H in Laron dwarfism; abolishes receptor homodimerization. | VAR_002713 | ||||||||||||||||||||||||||||||||||
| Natural variant | 171 | 1 | I → T in Laron dwarfism; almost completely abolishes GH-binding at cell surface: 53% binding to membrane fractions. | VAR_018431 | ||||||||||||||||||||||||||||||||||
| Natural variant | 172 | 1 | Q → P in Laron dwarfism; almost completely abolishes GH-binding at cell surface and in membrane fractions. | VAR_018432 | ||||||||||||||||||||||||||||||||||
| Natural variant | 173 | 1 | V → G in Laron dwarfism; almost completely abolishes GH-binding at cell surface: 26% binding to membrane fractions. | VAR_018433 | ||||||||||||||||||||||||||||||||||
| Natural variant | 179 | 1 | R → C in Laron dwarfism and short stature; idiopathic autosomal. | VAR_002714 | ||||||||||||||||||||||||||||||||||
| Natural variant | 179 | 1 | R → H: dbSNP rs6181. | VAR_013937 | ||||||||||||||||||||||||||||||||||
| Natural variant | 226 | 1 | Y → C in Laron dwarfism. | VAR_018434 | ||||||||||||||||||||||||||||||||||
| Natural variant | 229 | 1 | R → G in Laron dwarfism. | VAR_002715 | ||||||||||||||||||||||||||||||||||
| Natural variant | 229 | 1 | R → H in short stature; idiopathic autosomal. dbSNP rs6177. | VAR_013938 | ||||||||||||||||||||||||||||||||||
| Natural variant | 242 | 1 | E → D in short stature; idiopathic autosomal. | VAR_002716 | ||||||||||||||||||||||||||||||||||
| Natural variant | 244 | 1 | S → I in Laron dwarfism. | VAR_018435 | ||||||||||||||||||||||||||||||||||
| Natural variant | 262 | 1 | D → N in Laron dwarfism. | VAR_018436 | ||||||||||||||||||||||||||||||||||
| Natural variant | 440 | 1 | C → F in Laron dwarfism. dbSNP rs6182. | VAR_013939 | ||||||||||||||||||||||||||||||||||
| Natural variant | 465 | 1 | E → K: dbSNP rs34283856. | VAR_032704 | ||||||||||||||||||||||||||||||||||
| Natural variant | 495 | 1 | P → T: dbSNP rs6183. | VAR_013940 | ||||||||||||||||||||||||||||||||||
| Natural variant | 544 | 1 | I → L Polymorphism with a modifier effect on plasma HDL cholesterol levels in familial hypercholesterolemia patients. dbSNP rs6180. | VAR_013941 | ||||||||||||||||||||||||||||||||||
| Natural variant | 579 | 1 | P → T: dbSNP rs6184. | VAR_013942 | ||||||||||||||||||||||||||||||||||
Experimental info | ||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 260 | 1 | E → A: No change in shedding activity: No change in hormone binding | |||||||||||||||||||||||||||||||||||
| Mutagenesis | 261 | 1 | E → A: No change in shedding activity: No change in hormone binding | |||||||||||||||||||||||||||||||||||
| Mutagenesis | 262 | 1 | D → A: No change in shedding activity: No change in hormone binding | |||||||||||||||||||||||||||||||||||
Secondary structure | ||||||||||||||||||||||||||||||||||||||
Helix Strand Turn | ||||||||||||||||||||||||||||||||||||||
| Beta strand | 53 – 62 | 10 | ||||||||||||||||||||||||||||||||||||
| Beta strand | 64 – 68 | 5 | ||||||||||||||||||||||||||||||||||||
| Beta strand | 83 – 88 | 6 | ||||||||||||||||||||||||||||||||||||
| Beta strand | 111 – 114 | 4 | ||||||||||||||||||||||||||||||||||||
| Helix | 116 – 118 | 3 | ||||||||||||||||||||||||||||||||||||
| Beta strand | 121 – 131 | 11 | ||||||||||||||||||||||||||||||||||||
| Beta strand | 134 – 142 | 9 | ||||||||||||||||||||||||||||||||||||
| Helix | 143 – 146 | 4 | ||||||||||||||||||||||||||||||||||||
| Beta strand | 153 – 159 | 7 | ||||||||||||||||||||||||||||||||||||
| Beta strand | 167 – 176 | 10 | ||||||||||||||||||||||||||||||||||||
| Turn | 183 – 186 | 4 | ||||||||||||||||||||||||||||||||||||
| Beta strand | 190 – 198 | 9 | ||||||||||||||||||||||||||||||||||||
| Beta strand | 210 – 221 | 12 | ||||||||||||||||||||||||||||||||||||
| Beta strand | 226 – 234 | 9 | ||||||||||||||||||||||||||||||||||||
| Beta strand | 247 – 249 | 3 | ||||||||||||||||||||||||||||||||||||

Clusters with